ClinicalTrials.gg
Drug

Prabotulinumtoxin A clinical trials

Also written prabotulinumtoxinA, Jeuveau, ABP-450 and DWP450.

A product of Botulinum toxin type A; its studies count on that page too.

studies test it
18
open now
2
in phase 3
3
first study started
2015

How each study uses prabotulinumtoxin A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the prabotulinumtoxin A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Feb 2019 · Jeuveau · BLA 761085 (FDA, Purple Book)
European Union
27 Sept 2019 · Nuceiva · EMEA/H/C/004587 (EMA; as botulinum toxin type A)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Prabotulinumtoxin A
1

Brand

Jeuveau
5
Nabota
2

Development codes

ABP-450
4
DWP450
3

Other names

prabotulinumtoxinA
7
PrabotulinumtoxinA-Xvfs
3

Studies by the year they started

17 studies that test it; most in 2021 (6); 1 more planned to start later

Studies that test prabotulinumtoxin A, by start year
YearStudies
20152
20203
20216
20223
20231
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
3
Phase 2
6
Phase 3
3
Phase 4
3
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 9

AEON Biopharma, Inc. (4) · Daewoong Pharmaceutical Co. LTD. (3) · Yonsei University (2) · Evolus, Inc. (2) · University of Southern California (1) · Recep Tayyip Erdogan University (1) · University of Pennsylvania (1) · Lupo Center for Aesthetic and General Dermatology (1)

Often tested with

Tested in the same studies.

Onabotulinum toxin A (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test prabotulinumtoxin A.

Studies

Open first, then newest update. How each study uses prabotulinumtoxin A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18

Given beside what is tested · 1 — prabotulinumtoxin A is usual care or a partner of the new treatment

Codes

What other systems call prabotulinumtoxin A · ClinicalTrials.gg INT001089

  • UNII (FDA) 0A6JH35GMQPRABOTULINUMTOXIN AOne source FDA
  • RxNorm 2117869One source FDA
  • NCI Thesaurus C175750Prabotulinumtoxin AOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.